Sponsor:
University of Washington
Code:
NCT07721259
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
Biospecimen Collection
Brief summary:
Conditions
Anatomic Stage I Breast Cancer AJCC v8
Anatomic Stage II Breast Cancer AJCC v8
Anatomic Stage III Breast Cancer AJCC v8
Triple-Negative Breast Carcinoma
Study ID
NCT07721259
Start date
Dec 15, 2026
Status verified date
Jul, 2026
Completion date
Jul 16, 2030
Anticipated
Primary completion date
Jul 16, 2029
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
60 participants
Anticipated
Allocation
Randomized
Intervention Model
Parallel Assignment
Primary purpose
Treatment
Arms
experimental: Arm A (STEMVAC, GM-CSF)
active comparator: Arm B (GM-CSF)
Interventions
CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine
Recombinant Granulocyte-Macrophage Colony-Stimulating Factor
Biospecimen Collection
Primary outcome measure
Central contacts
Locations
Fred Hutch/University of Washington Cancer Consortium
Recruiting
Seattle, Washington, United States, 98109
Contacts
Principal Investigator:
Natasha Hunter, MD
Sponsor
University of Washington
Last update posted
Nov 19, 2026
Last verified
Jul, 2026
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-20. This information was provided to ClinicalTrials.gov by University of Washington on 2026-11-19. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.